Updated July 16, 2026
Clinical Editors: Danielle Brodeur, RN; Rebecca Musher Gross, MD; Danielle Newman, MD, MPH; Sara Huberman Carbone, MD; and Anh Le, MD
During the fall and winter season, the U.S. sees a surge in cases of respiratory syncytial virus, or RSV, among infants and children as well as adults. With hospitalizations on the rise, many parents are left wondering how to best protect their children. Here’s everything you need to know about the virus and keeping your family safe and healthy:
What is RSV?
RSV is a respiratory virus that generally presents during the fall and winter seasons, but it can occur any time of the year. It affects the lungs and breathing passages and typically causes mild, cold-like symptoms. It’s so common that virtually all children have at least one RSV infection by the time they are 2 years old. While anyone can be infected and most cases go undetected or resolve on their own, RSV can cause serious illness, especially in infants, young children, older adults, and those who are immunocompromised.
How is it transmitted?
RSV is transmitted through respiratory droplets, either through close contact with someone who has the virus or by touching an infected surface. RSV can survive on surfaces for several hours and on hands for about 30 minutes. People with RSV are usually contagious for 3 to 8 days, but some infants and people with weakened immune systems can be contagious for as long as 4 weeks, even if they’ve stopped showing symptoms.
What are the symptoms?
Many never develop symptoms at all. People with RSV who do develop symptoms typically begin to experience them 4 to 6 days after exposure. Like many other viral illnesses, common symptoms include:
- Runny nose
- Cough
- Sneezing
- Wheezing
- Fever
- Decrease in appetite
In the majority of cases, symptoms are mild and self limited. But sometimes — particularly in infants and young children — RSV can cause respiratory distress and progress into more severe conditions like bronchiolitis (inflammation of the small airways in the lungs) or pneumonia (infection of the lungs). RSV is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age.
If you notice more severe symptoms in your child - particularly persistent fever, decreased oral intake, or increased trouble breathing (such as pulling in the chest or neck, grunting, or wheezing) - reach out to your child’s primary care provider.
How can you prevent RSV?
There are currently a few immunization and vaccine options to prevent severe RSV infections for those who are most vulnerable. Here’s what you need to know:
RSV Immunization for Infants and Young Children
Nirsevimab (Beyfortus) and clesrovimab (Enflonsia) are both long-acting monoclonal antibodies recommended as first-line options for RSV prevention in infants. Different from the adult immunizations, these are not vaccines — they are monoclonal antibodies (proteins that provide direct protection against RSV) given by injection.
There is no preference for one product over the other. The choice may be guided by parent preference, product availability, and timing of the infant's birth relative to RSV season.
These products are recommended during RSV season (typically October through March in most of the continental United States) for:
- All infants younger than 8 months of age born during or entering their first RSV season, if the pregnant parent did not receive an RSV vaccine during pregnancy, the vaccination status is unknown, or the infant was born less than 14 days after the parent's RSV vaccination.
- Immunization is generally not needed for infants whose pregnant parent received the RSV vaccine at least 14 days before delivery. However, it may be considered in rare circumstances, such as when the pregnant parent was immunocompromised or the infant underwent cardiopulmonary bypass.
For a child’s second RSV season (ages 8–19 months), only nirsevimab is approved. It is recommended for children at high risk of severe RSV disease, including those with chronic lung disease of prematurity, severe immunocompromise, certain forms of cystic fibrosis, and for American Indian/Alaska Native children.
Timing
- Infants born during RSV season should receive their RSV immunization within 1 week of birth, ideally before hospital discharge or at the newborn well visit.
- Infants born outside of the RSV season but eligible for the immunization should receive it shortly before or during the RSV season.
- Infants undergoing cardiac surgery with cardiopulmonary bypass should receive an additional dose of nirsevimab or clesrovimab after surgery.
RSV Immunization for Pregnant People:
Abrysvo (Pfizer) is the only RSV vaccine approved for use during pregnancy. It is given as a single dose between 32 weeks and 36 weeks 6 days of gestation to protect newborns from severe RSV disease during the first 6 months of life.
If given ≥14 days before delivery, the infant generally does not also need a monoclonal antibody, with exceptions for immunocompromised mothers, conditions reducing transplacental transfer, or high-risk infants.
- Abrysvo should be given to pregnant people seasonally, from September through January in most of the continental United States. This timing ensures that infants are born with the highest levels of protection during RSV season.
- Providers in areas with different RSV seasonality (such as Alaska, southern Florida, Hawaii, and U.S. territories) should follow local public health guidance, as recommended timing may be different.
- Abrysvo can be given at the same visit as other recommended vaccines during pregnancy, including Tdap, influenza, and COVID-19 vaccines.
- Subsequent pregnancies: Additional doses of Abrysvo in subsequent pregnancies are not recommended at this time. There is no data on whether a prior dose provides protection for infants born in future pregnancies. Infants born to individuals who received Abrysvo during a previous pregnancy should receive nirsevimab or clesrovimab instead.
RSV Vaccines Available for Adults:
There are three FDA-approved vaccines for all adults > 60 years and for adults 18–59 years who are at increased risk: Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna). . Abrysvo (Pfizer) is the only one approved during pregnancy. For all other adults, the choice may be guided by product availability or patient preference.
- Ages 75 and older: A single dose of any of the three RSV vaccines is recommended for all adults in this age group who have not been previously vaccinated.
- Ages 60–74: A single dose of any of the three RSV vaccines is recommended for adults who are at increased risk for severe RSV disease. Shared decision making can be used for adults in this age group who may be at risk due to exposure to young children (ie grandchildren).
- Ages 50–59: Adults at increased risk for severe RSV disease may receive a single dose of RSV vaccine.
- Ages 18–49: The FDA has approved RSV vaccines for adults ages 18–49 who are at increased risk for severe RSV disease, but at this time, there is no recommendation from the CDC/ACIP for use in this age group.
Increased risk includes: chronic medical conditions (such as chronic heart or lung disease, diabetes, kidney or liver disorders), moderate or severe immune compromise, frailty, or living in a nursing home or long-term care facility.
Important notes:
- RSV vaccination is currently recommended as a single dose only. Adults who have already received an RSV vaccine - at any age - should not receive another dose at this time.
- RSV vaccine can be given at any time but is best administered in late summer or early fall (ideally August through October in most of the continental United States) before RSV season begins.
- There is no preference for one vaccine product over another among those licensed for a given age group.
Prevention measures for all ages
Fortunately, many of the same measures we take to prevent the spread of COVID-19 and the flu can protect against RSV. These include:
- Avoid close contact with people who are sick.
- Keep children home from daycare, school, activities, or from close contact with others when they have respiratory symptoms. Be mindful of others in your household as well.
- Cover coughs or sneezes with a tissue, then throw the tissue in the trash.
- Wash hands often with soap and water for at least 20 seconds, and if soap and water aren’t available, use an alcohol-based hand sanitizer. A trick to encouraging 20 seconds of handwashing is having your child wash a toy while washing their hands or singing one of their favorite songs. Singing “Happy Birthday” twice, for instance, will indicate when they can stop. You should encourage your child to wash their hands upon entering the house, after using the restroom, and before eating.
- Avoid touching eyes, nose, and mouth with unwashed hands and encourage your child to do the same.
- Clean and disinfect frequently touched toys and surfaces with a householder cleaner daily. This includes tables, doorknobs, light switches, remotes, handles, desks, toilets, phones, and tablets.
How is RSV treated?
At this time, there is no antiviral medication for treating RSV. Most RSV infections resolve on their own in 1-2 weeks. Just as with any other viral illness, your child should stay home and avoid contact with other people except to get medical care. Your child should rest, stay hydrated and take a fever-reducing medicine like ibuprofen or acetaminophen if needed. It’s important to note that children under 19 years old should not use aspirin unless directed to do so by their medical provider. RSV is viral, so antibiotics won’t help your child’s recovery.
In the case of severe infection, your child may need to be evaluated in a hospital setting in order to start more emergent supportive care and monitoring. When in doubt, please contact a member of our team for advice. We are here for you and want to keep all our families as healthy as possible during this cold season.
Have more questions about RSV? Our primary care team is here to help. At One Medical, we aim to provide exceptional care designed around your child’s unique health needs. Sign up today to book a same or next day appointment — in person or over video — through our app.
The One Medical blog is published by One Medical, a national, modern primary care practice pairing 24/7 virtual care services with inviting and convenient in-person care at over 100 locations across the U.S. One Medical is on a mission to transform health care for all through a human-centered, technology-powered approach to caring for people at every stage of life.
Any general advice posted on our blog, website, or app is for informational purposes only and is not intended to replace or substitute for any medical or other advice. 1Life Healthcare, Inc. and the One Medical entities make no representations or warranties and expressly disclaim any and all liability concerning any treatment, action by, or effect on any person following the general information offered or provided within or through the blog, website, or app. If you have specific concerns or a situation arises in which you require medical advice, you should consult with an appropriately trained and qualified medical services provider.